Dihydropyrimidine Dehydrogenase 85T>C Mutation Is Associated with Ocular Toxicity of 5-Fluorouracil: A Case Report

American Journal of Therapeutics

Volumn 22, Issue 2, 2015, Pages e36-e39

  Baskin, Yasemin ^a   Amirfallah, Arsalan ^a   Unal, Olcun Umit ^b   Calibasi, Gizem ^a   Oztop, Ilhan ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b ATATÜRK UNIVERSITY   (Turkey)

Author keywords

5 fluorouracil; dihydropyrimidine dehydrogenase; mutation; ocular toxicity

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; FOLINIC ACID; GENOMIC DNA; ANTINEOPLASTIC ANTIMETABOLITE;

ADJUVANT CHEMORADIOTHERAPY; ADULT; ADVANCED CANCER; ALLELE; ARTICLE; BOLUS INJECTION; CANCER PATIENT; CASE REPORT; COLONOSCOPY; COMPUTER ASSISTED TOMOGRAPHY; CONJUNCTIVITIS; ERYTHROCYTE; EYE PAIN; EYE TOXICITY; FEMALE; GENE MUTATION; GENETIC ANALYSIS; HAND FOOT SYNDROME; HEMATOCRIT; HUMAN; LEUKOCYTE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTOPHOBIA; PRIORITY JOURNAL; RECTUM ANTERIOR RESECTION; RECTUM BIOPSY; RECTUM CARCINOMA; RECTUM HEMORRHAGE; RECTUM ULCER; CHEMICALLY INDUCED; EYE DISEASE; GENETICS; HAND-FOOT SYNDROME; MUTATION; PHARMACOGENETICS; RECTAL NEOPLASMS;

ALLELES; ANTIMETABOLITES, ANTINEOPLASTIC; DIHYDROURACIL DEHYDROGENASE (NADP); EYE DISEASES; FEMALE; FLUOROURACIL; HAND-FOOT SYNDROME; HUMANS; MIDDLE AGED; MUTATION; PHARMACOGENETICS; RECTAL NEOPLASMS;

EID: 84925068221     PISSN: 10752765     EISSN: 15363686     Source Type: Journal    
DOI: 10.1097/MJT.0b013e31829e8516     Document Type: Article

References (22)

1. Ezzeldin H, Diasio RB. Dihydropyrimidine dehydrogenase deficiency, a pharmacogenetic syndrome associated with potentially life-threatening toxicity following 5-fluorouracil administration. Clin Colorectal Cancer. 2004;4:181-189.
2. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by The German 5-FU Toxicity Study Group. J Clin Oncol. 2008;26:2131-2138.
3. Singh P, Singh A. Ocular adverse effects of anti-cancer chemotherapy. J Cancer Ther Res. 2012;1:1-5.
4. Hsiao HH, Yang MY, Chang JG, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol. 2004;53:445-451.
5. Sobrero AF, Aschele C, Bertino JR. Fluorouracil in colorectal cancer - a tale of two drugs: implications for biochemical modulation. J Clin Oncol. 1997;15:368-381.
6. Lecomte T, Ferraz JM, Zinzindohoué F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res. 2004;10:5880-5888.
7. Afzal S, Jensen SA, Vainer B, et al. MTHFR polymorphisms and 5-FU-based adjuvant chemotherapy in colorectal cancer. Ann Oncol. 2009;20:1660-1666.
8. Kim SR, Park CH, Park S, et al. Genetic polymorphisms associated with 5-Fluorouracil-induced neurotoxicity. Chemotherapy. 2010;56:313-317.
9. Levy E, Piedbois P, Buyse M, et al. Toxicity of fluorouracil in patients with advanced colorectal cancer: effect of administration schedule and prognostic factors. Meta-Analysis Group in Cancer. J Clin Oncol. 1998;16:3537-3541.
10. Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 1989; 34:209-230.
11. Jansman FG, Sleijfer DT, de Graaf JC, et al. Management of chemotherapy-induced adverse effects in the treatment of colorectal cancer. Drug Saf. 2001;24:353-367.
12. Khaw PT, Sherwood MB, MacKay SL, et al. Five-minute treatments with fluorouracil, floxuridine, and mitomycin have long-term effects on human Tenon's capsule fibroblasts. Arch Ophthalmol. 1992;110:1150-1154.
13. Schmid KE, Kornek GV, Scheithauer W, et al. Update on ocular complications of systemic cancer chemotherapy. Surv Ophthalmol. 2006;51:19-40.
14. Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics. 2002;3:485-492.
15. Van Kuilenburg AB, Vreken P, Beex LV, et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur J Cancer. 1997;33:2258-2264.
16. Deenen MJ, Tol J, Burylo AM, et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res. 2011;17: 3455-3468.
17. Lazar A, Mau-Holzmann UA, Kolb H, et al. Multiple organ failure due to 5-fluorouracil chemotherapy in a patient with a rare dihydropyrimidine dehydrogenase gene variant. Onkologie. 2004;27:559-562.
18. Obi EE, McDonald A, Kemp E. A bilateral cicatricial ectropion and bilateral upper lid shortening caused by 5-fluorouracil toxicity in a patient with dihydropyrimidine dehydrogenase deficiency. Cutan Ocul Toxicol. 2011; 30:157-159.
19. Ben Fredj R, Gross E, Chouchen L, et al. Mutational spectrum of dihydropyrimidine dehydrogenase gene (DPYD) in the Tunisian population. C R Biol. 2007;330: 764-769.
20. Seck K, Riemer S, Kates R, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individuals. Clin Cancer Res. 2005;11: 5886-5892.
21. van Kuilenburg AB, Haasjes J, Richel DJ, et al. 5-Fluorouracil-associated toxicity: identification of new (DPD) deficiency in patients with severe clinical implications of dihydropyrimidine dehydrogenase mutations in the DPD gene. Clin Cancer Res. 2000;6:4705-4712.
22. Teitelbaum A. Eye symptoms and toxicities of systemic chemotherapy. In: Olver IN, ed. The MASCC Textbook of Cancer Supportive Care and Survivorship. Boston, MA: Springer; 2011:333-347.